Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer

IMPORTANCE: Combining conventional chemotherapy with targeted therapy has been proposed to improve the pathologic complete response (pCR) rate in patients with inflammatory breast cancer (IBC). Epidermal growth factor receptor (EGFR) expression is an independent predictor of low overall survival in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Matsuda, Naoko, Wang, Xiaoping, Lim, Bora, Krishnamurthy, Savitri, Alvarez, Ricardo H., Willey, Jie S., Parker, Charla A., Song, Juhee, Shen, Yu, Hu, Jianhua, Wu, Wenhui, Li, Nan, Babiera, Gildy V., Murray, James L., Arun, Banu K., Brewster, Abenaa M., Reuben, James M., Stauder, Michael C., Barnett, Chad M., Woodward, Wendy A., Le-Petross, H. T. Carisa, Lucci, Anthony, DeSnyder, Sarah M., Tripathy, Debu, Valero, Vicente, Ueno, Naoto T.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2018
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6143003/
https://ncbi.nlm.nih.gov/pubmed/29879283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.1436
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados